Polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyrdazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof

A pharmaceutical composition comprising a therapeutically effective amount of a 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride solvate excluding 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride monohydrate crystalline modification H2:

• Form H2:
• °2θ (Cu—Kα1
• Peak No.
• d/Å
• radiation) ± 0.1°
• (h, k, l)
• 1
• 8.71
• 10.1
• (1, 0, 0)
• 2
• 8.22
• 10.8
• (−1, 1, 1)
• 3
• 7.59
• 11.6
• (1, 2, 0)
• 4
• 6.78
• 13.0
• (0, 3, 1)
• 5
• 6.58
• 13.5
• (−1, 3, 1)
• 6
• 5.73
• 15.4
• (−1, 4, 1)
• 7
• 4.98
• 17.8
• (−1, 1, 2)
• 8
• 4.84
• 18.3
• (−2, 1, 1)
• 9
• 4.68
• 19.0
• (−2, 2, 1)
• 10
• 4.43
• 20.0
• (−2, 3, 1)
• 11
• 4.35
• 20.4
• (2, 0, 0)
• 12
• 3.73
• 23.9
• (−2, 4, 2)
• 13
• 3.64
• 24.5
• (0, 5, 2)
• 14
• 3.39
• 26.3
• (0, 6, 2)
• 15
• 3.13
• 28.5
• (−3, 2, 2)
• and
• a therapeutically effective amount of at least one additional pharmaceutically active substance selected from C225 and Erlotinib.